GlassScriptPhysician profile
Cindy Parnes
NPI 1548289853
$31,671.18
in general payments reported to CMS, 2019-2025
29 companies · $3,889 in 2025
The $3,889 reported for 2025 was more than what 97% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $228 · 2020: $173 · 2021: $342 · 2022: $158 · 2023: $16K · 2024: $11K · 2025: $3,889.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $23K · Travel and Lodging: $5,421 · Food and Beverage: $1,724 · Education: $226.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $23,400.00 |
| Travel and Lodging | $5,421.25 |
| Food and Beverage | $1,723.52 |
| Education | $225.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $30,195.26 | 2022-2025 | Veozah, Myrbetriq |
| Pfizer INC. | $192.25 | 2019-2023 | |
| Novo Nordisk INC | $183.93 | 2022-2025 | Wegovy |
| Abbvie INC. | $150.29 | 2019-2023 | |
| Evofem Biosciences, INC. | $98.45 | 2021-2022 | |
| Amgen INC. | $93.06 | 2021-2025 | Evenity, Prolia |
| Therapeuticsmd, INC. | $91.68 | 2019-2021 | |
| Lifenet Health | $84.28 | 2025 | Graftlink |
| Lupin INC. | $68.41 | 2019-2020 | |
| Avion Pharmaceuticals | $56.49 | 2021-2023 | Balcoltra |
| Millicent US INC | $45.73 | 2024 | Intrarosa, Femring |
| Organon LLC | $44.43 | 2021-2024 | |
| Mayne Pharma Commercial LLC | $43.04 | 2021-2023 | |
| Virtus Pharmaceuticals LLC | $39.66 | 2021 | |
| Lilly USA, LLC | $39.18 | 2024-2025 | Zepbound |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exeltis, USA INC. | $37.80 | 2024-2025 | Slynd |
| Medtronic Vascular, INC. | $26.03 | 2019 | |
| Seapearl East, INC | $21.06 | 2025 | |
| Bausch Health US, LLC | $18.83 | 2021 | |
| Meditrina | $17.00 | 2023 | |
| Vertical Pharmaceuticals, LLC | $15.00 | 2019 | |
| Endo Pharmaceuticals INC. | $15.00 | 2021 | |
| Sumitomo Pharma America, INC. | $14.81 | 2023 | Myfembree |
| Eisai INC. | $14.66 | 2019 | |
| Minerva Surgical, INC | $13.69 | 2019 | |
| Mylan Pharmaceuticals INC. | $13.25 | 2022 | |
| Agile Therapeutics, INC. | $12.79 | 2022 | |
| Merck Sharp & Dohme LLC | $12.69 | 2020 | |
| Duchesnay USA Incorporated | $12.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cindy Parnes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.